Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Sir Mortimer B. Davis - Jewish General Hospital Merck Frosst Canada Ltd. |
---|---|
Information provided by: | Sir Mortimer B. Davis - Jewish General Hospital |
ClinicalTrials.gov Identifier: | NCT00388388 |
This randomized, double-blind, parallel group, two-centre pilot study will test the hypothesis that subjects who are otherwise healthy but fulfill the criteria for a diagnosis of pre-hypertension and pre-diabetes will have regression or reduced progression of hypertension-associated changes in their resistance arteries if their blood pressure is controlled for 6 months with losartan, whereas similar subjects whose blood pressure is equally well controlled using hydrochlorothiazide will have significantly less improvement of the changes in their resistance arteries.
Condition | Intervention | Phase |
---|---|---|
Pre-Hypertension Pre-Diabetes |
Drug: losartan, hydrochlorothiazide |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Double-Blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-Hypertensive Pre-Diabetic Subjects |
Estimated Enrollment: | 30 |
Study Start Date: | March 2007 |
Ages Eligible for Study: | 25 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Ernesto L. Schiffrin, MD, PhD | 514-340-8222 ext 4835 | ernesto.schiffrin@mcgill.ca |
Contact: Ranjan Sudra | 514-340-7538 | rsudra@mtd.jgh.mcgill.ca |
Canada, Quebec | |
Cardiovascular Prevention Centre, Jewish General Hospital | Recruiting |
Montreal, Quebec, Canada, H3T 1E2 | |
Contact: Ernesto L. Schiffrin, MD, PhD 514-340-8222 ext 4030 ernesto.schiffrin@mcgill.ca | |
Contact: Tracy Hodge, RN 514-340-8222 ext 4030 tract.hodge@jgh.mcgill.ca | |
Principal Investigator: Ernesto L. Schiffrin, MD, PhD |
Principal Investigator: | Ernesto L. Schiffrin, MD, PhD | Physician-Chief, SMBD - Jewish General Hospital & Professor of Medicine, McGill University |
Study ID Numbers: | CPC030 |
Study First Received: | October 13, 2006 |
Last Updated: | April 30, 2007 |
ClinicalTrials.gov Identifier: | NCT00388388 |
Health Authority: | Canada: Health Canada; Canada: Ethics Review Committee |
Remodeling Resistance arteries angiotensin receptor blocker thiazide diuretic |
Losartan Metabolic Diseases Glucose Intolerance Diabetes Mellitus Prediabetic State Disease Progression Vascular Diseases Endocrine System Diseases |
Angiotensin II Hydrochlorothiazide Hyperglycemia Endocrinopathy Glucose Metabolism Disorders Metabolic disorder Hypertension |
Molecular Mechanisms of Pharmacological Action Diuretics Physiological Effects of Drugs Sodium Chloride Symporter Inhibitors Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |
Membrane Transport Modulators Angiotensin II Type 1 Receptor Blockers Natriuretic Agents Therapeutic Uses Cardiovascular Diseases Anti-Arrhythmia Agents |